about
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive LifeRegulation of the 24h body temperature rhythm of women in luteal phase: role of gonadal steroids and prostaglandinsEffect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy.Modification of blood pressure in postmenopausal women: role of hormone replacement therapyHereditary ovarian cancer: not only BRCA 1 and 2 genes.Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking statusMacro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a post hoc analysis of REVIVE survey data.Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group.The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation.Pharmacokinetic evaluation of desogestrel as a female contraceptive.European society of contraception statement on contraception in obese women.Monurelle Biogel(®) vaginal gel in the treatment of vaginal dryness in postmenopausal women.ISPOG European Consensus Statement - chronic pelvic pain in women (short version).Does dienogest influence the inflammatory response of endometriotic cells? A systematic review.Metabolic impact of combined hormonal contraceptives containing estradiol.Association between pelvic organ prolapse and climacteric symptoms in postmenopausal women.Hormonal contraception: venous and arterial disease.Management of vaginal atrophy: a real mess. Results from the AGATA study.Use of contraception by women with induced abortion in Italy.Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases?Medical and patient attitude towards vaginal atrophy: the AGATA study.Association between urinary incontinence and climacteric symptoms in postmenopausal women.Season of birth influences the timing of menopause.Are climacteric complaints associated with risk factors of cardiovascular disease in peri-menopausal women?Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro.Kava-Kava administration reduces anxiety in perimenopausal women.[Evolution and future of contraception].Altered neuroendocrine regulation of luteinizing hormone secretion in postmenopausal women with Parkinson's disease.Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women.Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen.The ovarian response to controlled stimulation in IVF cycles may be predictive of the age at menopause.Endothelin-1 and nitric oxide levels are related to cardiovascular risk factors but are not modified by estradiol replacement in healthy postmenopausal women. A cross-sectional and a randomized cross-over study.Prolonged opioid blockade does not influence luteinizing hormone modifications of the follicular and luteal menstrual phases.Interaction between veralipride and the endogenous opioid system in the regulation of body temperature in postmenopausal women.Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel.Early outcome of myomectomy by laparotomy, minilaparotomy and laparoscopically assisted minilaparotomy. A randomized prospective study.Relation of homocysteine, folate, and vitamin B12 to bone mineral density of postmenopausal women.Comparison of the effect of oral and transdermal hormone therapy on fasting and postmethionine homocysteine levels.Administration of tibolone decreases 24 h heart rate but not blood pressure of post-menopausal women.A comparison of the central effects of different progestins used in hormone replacement therapy.
P50
Q26785614-78DE246F-094C-4842-98D3-5B741718DBEAQ28193613-1FA3435C-7115-4D6A-B04E-E19CB4358ADBQ32027125-33D2A8D7-79AB-4A9F-942B-E84B7BD33C7EQ34062334-09050169-5299-41C5-951F-272766B05EADQ34480707-18ED37D4-BABD-49C2-94E8-851990980883Q34625478-56B8C6BD-0263-476A-9D9F-D326D1D82667Q36301955-4A8606C5-5B06-4D97-862A-880585D70AD9Q37494813-D0656792-CAF0-4847-8C63-839218F3432FQ37705926-69BD2932-8D2A-4F20-A97F-1E3434774494Q38150419-78B4E757-6805-4817-8BF2-8FC175C69125Q38266121-549D0702-655B-4595-A45F-5EFEAC76DDCAQ38374840-A9056D0A-F78F-4DFA-BF16-561D737F5C66Q38619661-4126F061-AB4B-4023-B936-843BF28944CDQ38663754-354B5B03-576B-452F-8E84-E292B6DB25E8Q38836319-D1895888-6AE0-4F9B-95EE-BFD171EA0653Q38863175-B4D75CF4-D871-454A-ABBD-5E00FA573765Q38870757-BA798530-7217-498A-953C-372B6A4887E2Q39157271-57F7E976-54D7-4AAF-B42B-027426C30D0DQ39197813-13285132-74A7-4FB9-BEA1-83E3A28DB407Q39269760-12F65027-DADF-4F21-AABD-614BD2DA830DQ39295958-AB739E21-6A75-46FF-8AD4-ED93BD6942CAQ39371390-8A70CC82-9068-4BEC-AF94-6DB112A0BAF3Q40423166-499BF196-260B-4D65-8BEF-67AF701C50C3Q41587693-89794053-9328-4594-A059-7F5DB2AECEFBQ42487371-CD656458-583E-4A29-9EA6-DA1DF2F826A0Q42694889-0910F9EF-FFCA-4D32-8DBA-0DE21334A9FBQ42912865-133EFB10-8A9F-4ED3-BF78-803DAC2FFF97Q43957673-350B2006-CAC4-40BF-9931-E9458735694AQ44126976-67A0F700-C6BB-44C0-AD14-454509EC968EQ44166478-1640167F-B93E-455E-A468-B733EFBFC432Q44217070-E6A2650F-5294-4A0C-A3F2-76240B2466ACQ44317930-6C2A3D80-45AA-454D-912D-3EF900C3B0A8Q44336060-071A8025-B832-4BCF-B302-070571D5380AQ44349124-672DA999-FE57-4EC6-927E-CF8FC952EC81Q44547514-3E0543EF-D0A6-450F-8DE7-EF189C0F4787Q44673968-89CB341C-EE95-42E1-B3EC-753E90271687Q44695648-402D4B01-E7FA-47C8-B20D-029EC82FCF9AQ44719036-A319F243-58F4-47CC-950C-DA33533C0566Q44917278-B8D42E93-22F3-415F-AC18-A9CBDE944018Q45000219-8CC98B74-AD55-47C0-B6FA-0F12ADD2D78B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Angelo Cagnacci
@ast
Angelo Cagnacci
@en
Angelo Cagnacci
@es
Angelo Cagnacci
@nl
Angelo Cagnacci
@sl
type
label
Angelo Cagnacci
@ast
Angelo Cagnacci
@en
Angelo Cagnacci
@es
Angelo Cagnacci
@nl
Angelo Cagnacci
@sl
prefLabel
Angelo Cagnacci
@ast
Angelo Cagnacci
@en
Angelo Cagnacci
@es
Angelo Cagnacci
@nl
Angelo Cagnacci
@sl
P1053
Q-7432-2016
P106
P1153
7005516868
P21
P31
P3829
P496
0000-0003-2714-623X